Lipum AB (publ)

Stockholm Stock Exchange LIPUM.ST

Lipum AB (publ) Gross Profit for the year ending December 31, 2023: USD 5.23 K

Lipum AB (publ) Gross Profit is USD 5.23 K for the year ending December 31, 2023, a 597.96% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Lipum AB (publ) Gross Profit for the year ending December 31, 2022 was USD -1.05 K, a 0.00% change year over year.
Lipum AB (publ) Gross Profit for the year ending December 31, 2021 was USD 0.00, a 100.00% change year over year.
Lipum AB (publ) Gross Profit for the year ending December 31, 2020 was USD -3.85 M, a -92.53% change year over year.
Lipum AB (publ) Gross Profit for the year ending December 31, 2019 was USD -2.00 M, a -932,805.49% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

Stockholm Stock Exchange: LIPUM.ST

Lipum AB (publ)

CEO	Mr. Ola Sandborgh
IPO Date	April 22, 2021
Location	Sweden
Headquarters	Tvistevägen 48C
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was founded in 2010 and is headquartered in Umeå, Sweden.

Key trends

Past 5 years